Salivary progesterone and estriol among pregnant women treated with 17-α-hydroxyprogesterone caproate or placebo

Mark A. Klebanoff, Paul J. Meis, Mitchell P. Dombrowski, Yuan Zhao, Atef H. Moawad, Allison Northen, Baha M. Sibai, Jay D. Iams, Michael W. Varner, Steve N. Caritis, Mary J. O'Sullivan, Kenneth J. Leveno, Menachem Miodovnik, Deborah Conway, Ronald J. Wapner, Marshall Carpenter, Brian M. Mercer, Susan M. Ramin, John M. Thorp, Alan M. Peaceman

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Objective: The objectives of the study was to determine whether salivary progesterone (P) or estriol (E3) concentration at 16-20 weeks' gestation predicts preterm birth or the response to 17α-hydroxyprogesterone caproate (17OHPC) and whether 17OHPC treatment affected the trajectory of salivary P and E3 as pregnancy progressed. Study Design: This was a secondary analysis of a clinical trial of 17OHPC to prevent preterm birth. Baseline saliva was assayed for P and E3. Weekly salivary samples were obtained from 40 women who received 17OHPC and 40 who received placebo in a multicenter randomized trial of 17OHPC to prevent recurrent preterm delivery. Results: Both low and high baseline saliva P and E3 were associated with a slightly increased risk of preterm birth. However, 17OHPC prevented preterm birth comparably, regardless of baseline salivary hormone concentrations. 17OHPC did not alter the trajectory of salivary P over pregnancy, but it significantly blunted the rise in salivary E3 as well as the rise in the E3/P ratio. Conclusion: 17OHPC flattened the trajectory of E3 in the second half of pregnancy, suggesting that the drug influences the fetoplacental unit.

Original languageEnglish (US)
JournalAmerican Journal of Obstetrics and Gynecology
Volume199
Issue number5
DOIs
StatePublished - Nov 2008

Fingerprint

17-alpha-Hydroxyprogesterone
Estriol
Premature Birth
Progesterone
Pregnant Women
Placebos
Pregnancy
Saliva
Multicenter Studies
Clinical Trials
Hormones
17-alpha-hydroxy-progesterone caproate
Pharmaceutical Preparations

Keywords

  • 17-alpha-hydroxyprogesterone caproate
  • longitudinal studies
  • preterm birth
  • salivary estriol
  • salivary progesterone

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Salivary progesterone and estriol among pregnant women treated with 17-α-hydroxyprogesterone caproate or placebo. / Klebanoff, Mark A.; Meis, Paul J.; Dombrowski, Mitchell P.; Zhao, Yuan; Moawad, Atef H.; Northen, Allison; Sibai, Baha M.; Iams, Jay D.; Varner, Michael W.; Caritis, Steve N.; O'Sullivan, Mary J.; Leveno, Kenneth J.; Miodovnik, Menachem; Conway, Deborah; Wapner, Ronald J.; Carpenter, Marshall; Mercer, Brian M.; Ramin, Susan M.; Thorp, John M.; Peaceman, Alan M.

In: American Journal of Obstetrics and Gynecology, Vol. 199, No. 5, 11.2008.

Research output: Contribution to journalArticle

Klebanoff, MA, Meis, PJ, Dombrowski, MP, Zhao, Y, Moawad, AH, Northen, A, Sibai, BM, Iams, JD, Varner, MW, Caritis, SN, O'Sullivan, MJ, Leveno, KJ, Miodovnik, M, Conway, D, Wapner, RJ, Carpenter, M, Mercer, BM, Ramin, SM, Thorp, JM & Peaceman, AM 2008, 'Salivary progesterone and estriol among pregnant women treated with 17-α-hydroxyprogesterone caproate or placebo', American Journal of Obstetrics and Gynecology, vol. 199, no. 5. https://doi.org/10.1016/j.ajog.2008.03.003
Klebanoff, Mark A. ; Meis, Paul J. ; Dombrowski, Mitchell P. ; Zhao, Yuan ; Moawad, Atef H. ; Northen, Allison ; Sibai, Baha M. ; Iams, Jay D. ; Varner, Michael W. ; Caritis, Steve N. ; O'Sullivan, Mary J. ; Leveno, Kenneth J. ; Miodovnik, Menachem ; Conway, Deborah ; Wapner, Ronald J. ; Carpenter, Marshall ; Mercer, Brian M. ; Ramin, Susan M. ; Thorp, John M. ; Peaceman, Alan M. / Salivary progesterone and estriol among pregnant women treated with 17-α-hydroxyprogesterone caproate or placebo. In: American Journal of Obstetrics and Gynecology. 2008 ; Vol. 199, No. 5.
@article{076c7eac59044c95829fe0167eab1fd9,
title = "Salivary progesterone and estriol among pregnant women treated with 17-α-hydroxyprogesterone caproate or placebo",
abstract = "Objective: The objectives of the study was to determine whether salivary progesterone (P) or estriol (E3) concentration at 16-20 weeks' gestation predicts preterm birth or the response to 17α-hydroxyprogesterone caproate (17OHPC) and whether 17OHPC treatment affected the trajectory of salivary P and E3 as pregnancy progressed. Study Design: This was a secondary analysis of a clinical trial of 17OHPC to prevent preterm birth. Baseline saliva was assayed for P and E3. Weekly salivary samples were obtained from 40 women who received 17OHPC and 40 who received placebo in a multicenter randomized trial of 17OHPC to prevent recurrent preterm delivery. Results: Both low and high baseline saliva P and E3 were associated with a slightly increased risk of preterm birth. However, 17OHPC prevented preterm birth comparably, regardless of baseline salivary hormone concentrations. 17OHPC did not alter the trajectory of salivary P over pregnancy, but it significantly blunted the rise in salivary E3 as well as the rise in the E3/P ratio. Conclusion: 17OHPC flattened the trajectory of E3 in the second half of pregnancy, suggesting that the drug influences the fetoplacental unit.",
keywords = "17-alpha-hydroxyprogesterone caproate, longitudinal studies, preterm birth, salivary estriol, salivary progesterone",
author = "Klebanoff, {Mark A.} and Meis, {Paul J.} and Dombrowski, {Mitchell P.} and Yuan Zhao and Moawad, {Atef H.} and Allison Northen and Sibai, {Baha M.} and Iams, {Jay D.} and Varner, {Michael W.} and Caritis, {Steve N.} and O'Sullivan, {Mary J.} and Leveno, {Kenneth J.} and Menachem Miodovnik and Deborah Conway and Wapner, {Ronald J.} and Marshall Carpenter and Mercer, {Brian M.} and Ramin, {Susan M.} and Thorp, {John M.} and Peaceman, {Alan M.}",
year = "2008",
month = "11",
doi = "10.1016/j.ajog.2008.03.003",
language = "English (US)",
volume = "199",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - Salivary progesterone and estriol among pregnant women treated with 17-α-hydroxyprogesterone caproate or placebo

AU - Klebanoff, Mark A.

AU - Meis, Paul J.

AU - Dombrowski, Mitchell P.

AU - Zhao, Yuan

AU - Moawad, Atef H.

AU - Northen, Allison

AU - Sibai, Baha M.

AU - Iams, Jay D.

AU - Varner, Michael W.

AU - Caritis, Steve N.

AU - O'Sullivan, Mary J.

AU - Leveno, Kenneth J.

AU - Miodovnik, Menachem

AU - Conway, Deborah

AU - Wapner, Ronald J.

AU - Carpenter, Marshall

AU - Mercer, Brian M.

AU - Ramin, Susan M.

AU - Thorp, John M.

AU - Peaceman, Alan M.

PY - 2008/11

Y1 - 2008/11

N2 - Objective: The objectives of the study was to determine whether salivary progesterone (P) or estriol (E3) concentration at 16-20 weeks' gestation predicts preterm birth or the response to 17α-hydroxyprogesterone caproate (17OHPC) and whether 17OHPC treatment affected the trajectory of salivary P and E3 as pregnancy progressed. Study Design: This was a secondary analysis of a clinical trial of 17OHPC to prevent preterm birth. Baseline saliva was assayed for P and E3. Weekly salivary samples were obtained from 40 women who received 17OHPC and 40 who received placebo in a multicenter randomized trial of 17OHPC to prevent recurrent preterm delivery. Results: Both low and high baseline saliva P and E3 were associated with a slightly increased risk of preterm birth. However, 17OHPC prevented preterm birth comparably, regardless of baseline salivary hormone concentrations. 17OHPC did not alter the trajectory of salivary P over pregnancy, but it significantly blunted the rise in salivary E3 as well as the rise in the E3/P ratio. Conclusion: 17OHPC flattened the trajectory of E3 in the second half of pregnancy, suggesting that the drug influences the fetoplacental unit.

AB - Objective: The objectives of the study was to determine whether salivary progesterone (P) or estriol (E3) concentration at 16-20 weeks' gestation predicts preterm birth or the response to 17α-hydroxyprogesterone caproate (17OHPC) and whether 17OHPC treatment affected the trajectory of salivary P and E3 as pregnancy progressed. Study Design: This was a secondary analysis of a clinical trial of 17OHPC to prevent preterm birth. Baseline saliva was assayed for P and E3. Weekly salivary samples were obtained from 40 women who received 17OHPC and 40 who received placebo in a multicenter randomized trial of 17OHPC to prevent recurrent preterm delivery. Results: Both low and high baseline saliva P and E3 were associated with a slightly increased risk of preterm birth. However, 17OHPC prevented preterm birth comparably, regardless of baseline salivary hormone concentrations. 17OHPC did not alter the trajectory of salivary P over pregnancy, but it significantly blunted the rise in salivary E3 as well as the rise in the E3/P ratio. Conclusion: 17OHPC flattened the trajectory of E3 in the second half of pregnancy, suggesting that the drug influences the fetoplacental unit.

KW - 17-alpha-hydroxyprogesterone caproate

KW - longitudinal studies

KW - preterm birth

KW - salivary estriol

KW - salivary progesterone

UR - http://www.scopus.com/inward/record.url?scp=54849431804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54849431804&partnerID=8YFLogxK

U2 - 10.1016/j.ajog.2008.03.003

DO - 10.1016/j.ajog.2008.03.003

M3 - Article

VL - 199

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 5

ER -